Next, we have tested whether two cycles of FMD enhances the efficacy of another immunotherapy treatment in melanoma by combining antagonist antibody against immune checkpoint PD-L1 and agonist antibody against costimulatory molecule OX40. The gene discussed is CD274; the disease is melanoma.